Citation Tools

Download PDFPDF

Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas

Download to a citation manager

Cite this article as:
Fiedler W, Cresta S, Schulze-Bergkamen H, et al
Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas